Viz.ai to Expedite Patient Enrollment in NIH-funded PE-TRACT Clinical Trial
Viz.ai, the leader in AI-powered disease detection and care coordination, today announced it will use its VizTM RECRUIT platform to optimize patient enrollment for the NIH-funded1 Pulmonary Embolism—Thrombus Removal with Catheter-Directed Thrombolysis (PE-TRACT) clinical trial. The PE-TRACT trial will be the most rigorous randomized controlled clinical trial to date of catheter-directed therapy for pulmonary embolism, with plans to enroll 500 patients across 30-50 sites.
The PE-TRACT trial is designed to address whether catheter therapy should be routinely used to treat intermediate-risk pulmonary embolism versus anticoagulants alone. Pulmonary embolism occurs when a blood clot is trapped in an artery in the lung, blocking blood flow to part of the lung.
“The PE-TRACT trial will offer a deeper knowledge of pulmonary embolism by providing a comprehensive comparison of catheter-directed therapy plus anticoagulation to anticoagulation alone,” said Dr. Akhilesh Sista, [Principal Investigator of the PE-TRACT trial, Interventional Radiologist and Faculty, Weill Cornell Medical College]. “PE-TRACT will provide valuable insights to patients and providers regarding which approach best maintains cardiopulmonary health in the year following PE. Viz.ai’s RECRUIT tool has the potential to efficiently identify potential participants and help this important trial complete enrollment on time.”
Participating research institutions in the PE-TRACT trial will use Viz RECRUIT to find, screen, and enroll clinical trial candidates. Viz RECRUIT, an AI-powered clinical trial enrollment platform, automates the identification and triage of eligible candidates for pre-trial review, while reducing the burden on the research team. Using Viz RECRUIT, sites will be able to automatically screen patients based on pulmonary embolism and high right ventricular to left ventricular diameter (RV/LV) ratio. The cloud-based technology helps to broaden the recruitment funnel in both size and diversity and streamlines the trial enrollment workflow. To date, Viz RECRUIT has been used to screen nearly 300,000 patients and identify over 14,000 clinical trial candidates across 100 healthcare facilities.
“We’re honored to be the partner of choice for this clinical trial to accelerate vascular research using Viz RECRUIT. With our platform’s real-world accuracy and demonstrated success, researchers can use AI to identify potentially eligible trial candidates, regardless of their location, ultimately expediting the clinical trial enrollment process,” said Jayme Strauss, chief clinical officer, Viz.ai. “We aim to expand the participation and diversity of participants in clinical research to make treatments safer for all patients and advance the development of novel treatments, while empowering research teams to efficiently and consistently screen for patients and coordinate research.”
Information on the PE-TRACT trial and the Viz RECRUIT platform will be presented at the upcoming Society of Interventional Radiology Meeting on March 7 in Phoenix, Arizona. To learn more, please visit the Viz.ai website.
1 The study was funded by the National Heart, Lung, and Blood Institute, of the National Institutes of Health, under grant award number 1UG3HL155798-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase access to life-saving treatments, covering more than 200 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230304005004/en/
Contact information
Ariane Lovell
ariane.lovell@finnpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Transition Industries Signs Strategic Agreements for the Pacifico Mexinol Project, the Largest Standalone Ultra-Low Carbon Chemical Production Facility in the World30.6.2025 21:30:00 EEST | Press release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and green hydrogen projects in North America, held a signing event for an Engineering, Procurement, and Construction (EPC) contract with the consortium of Samsung E&A Co., Ltd. (Samsung E&A), Grupo Samsung E&A Mexico, S.A. de C.V., and Techint Engineering and Construction for the Pacifico Mexinol project located in Ahome, Sinaloa, Mexico, which is contingent upon the fulfillment of customary conditions precedent and obtainment of all required approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630940954/en/ MAIRE group’s technology division NextChem, through its subsidiary KT TECH SpA, also signed a Basic Engineering, Critical and Proprietary Equipment Supply Agreement with Samsung E&A in connection with its proprietary NX AdWinMethanol®Zero technology supply to the project. Transition Industries is jointly developing the Pacif
Westinghouse and ITER Sign a $180M Contract to Advance Nuclear Fusion30.6.2025 16:45:00 EEST | Press release
Westinghouse Electric Company and ITER signed a contract for $180 million for the assembly of the vacuum vessel for the fusion reactor. This is a key milestone in the construction of the ITER reactor, leading the way toward the use of fusion as a practical future source of reliable carbon-free energy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630497810/en/ The ITER Tokamak pit with the two vacuum vessel sector modules installed. Westinghouse has participated in the fabrication of the sectors of the vacuum vessel, as part of the Fusion for Energy (F4E) Consortium with its partners Ansaldo Nucleare and Walter Tosto. Westinghouse will be responsible for completing the vacuum vessel which is ITER’s most critical component: a hermetically sealed, double-walled steel container that will house the fusion plasma. When all the vacuum vessel sectors are in place, Westinghouse will start the most intensive stage of ITER assembl
Monetate Acquires SiteSpect to Deliver AI-Native Personalization and Testing at Enterprise Scale30.6.2025 16:00:00 EEST | Press release
Monetate, the leading AI-driven personalization platform, today announced it has acquired SiteSpect, a leader in A/B testing, to drive next-generation digital experience optimization. This acquisition accelerates Monetate’s vision to deliver intelligent, intentional, and individualized experiences at scale, powered by agentic AI and backed by the industry’s most advanced, enterprise-grade infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630514541/en/ The combination of Monetate’s real-time personalization and SiteSpect’s zero-flicker testing will yield an industry-first solution for enterprise-grade personalization, testing, and optimization. For the first time, global ecommerce and digital experience leaders can access unified client-side and server-side experimentation with full personalization capabilities in a single solution, designed for scalability and regulatory compliance. Monetate is now the only e
SS&C Blue Prism Recognized as a Gartner® Magic Quadrant™ RPA Leader for the Seventh Consecutive Year30.6.2025 16:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that SS&C Blue Prism has been recognized as a Leader in the 2025 Gartner Magic Quadrant for Robotic Process Automation (RPA). “We’re delighted SS&C Blue Prism has been named a Leader in the Gartner Magic Quadrant for Robotic Process Automation for the seventh year running,” said Bill Stone, CEO and Chairman of SS&C Technologies. “SS&C Blue Prism combines market-leading RPA and orchestration technologies with the latest artificial intelligence so organizations can tackle more complex tasks and dynamic business processes. We’ve scaled to more than 2,700 digital workers and AI agents across our own operations, resulting in over $200 million in annual savings. With SS&C leading the charge on deployment, customers can be confident in rolling out SS&C’s automation solutions securely, effectively, and responsibly.” More than 2,800 companies worldwide leverage SS&C Blue Prism for AI-powered automation, helping organizations delive
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content 130.6.2025 15:00:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD LIQUID ERC may help ease the administration burden for patients and their health care providers by eliminating the need for reconstitution and can be administered intravenously or subcutaneously.1 “The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the lowest IgA content of any ready-to-use liquid immunoglobulin therapy, and can be administered intravenously or subcutaneously,” said Kristina Allikmets, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom